The insider sales are routine post-earnings liquidity events tied to option exercises and do not signal bearish conviction. The more actionable signal is the Q1 earnings: a 2% revenue decline and 15% net income drop, with competitive pressure on Nebulized Tyvaso and rising costs. Monitor the next quarter for Tyvaso DPI growth sustainability and any guidance updates on the competitive landscape.
Price Chart
Executive Summary
A cluster of insider sales at United Therapeutics (UTHR) totaling $1.72M occurred within 8 days of a Q1 2026 earnings release showing a 2% YoY revenue decline and a 15% drop in net income. The sales are predominantly by the CEO (Martine Rothblatt) and CFO (James Edgemond), largely tied to option exercises, and represent only ~0.007% of the company's $24.6B market cap — a trivial amount. The earnings miss and competitive pressure on Nebulized Tyvaso are the more material signals, but the insider sales themselves are routine and non-informative.
Key Financial Metrics
Key Facts
- Total insider sales of $1.72M represent ~0.007% of UTHR's $24.6B market cap — far below the 0.1% materiality threshold.
- CEO Rothblatt sold ~$2.2M worth of shares across multiple days, all tied to option exercises (non-cash acquisition of shares).
- CFO Edgemond sold ~$734K, also tied to option exercises.
- Q1 2026 revenues fell 2% YoY to $781.5M; net income dropped 15% to $274.9M.
- Tyvaso DPI grew 9% YoY, but Nebulized Tyvaso declined 22%, and total Tyvaso revenues fell 2%.
- Cost of sales surged 44% YoY, partly due to a $26.8M inventory reserve from a commercial supply agreement.
- No open-market purchases by any insider in the cluster — all sales are either open-market or tied to option exercises.
- The cluster occurred within 8 days of the Q1 earnings release, a common pattern for post-earnings liquidity sales.
Financial Impact
Insider sales of $1.72M are negligible relative to $24.6B market cap. The earnings impact is more significant: revenue declined $12.9M (-2%) and net income fell $47.3M (-15%) YoY.
Risk Factors
- Continued erosion of Nebulized Tyvaso revenues could pressure total Tyvaso franchise growth.
- Cost of sales spike from inventory reserves may recur if commercial supply agreements remain unfavorable.
- No insider buying to offset the selling cluster — lack of bullish conviction from management.
- Competitive dynamics in inhaled prostacyclins remain a headwind per management commentary.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1778795706975 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $500.35 $497.31 | ▼ −0.61% | ▼ −2.72% | $571.38 (+14.20%) |
Sep 11, 2026 21d ago | Insider Cluster | $497.11 $494.63 | ▼ −0.50% | ▼ −0.28% | $571.38 (+14.94%) |
Sep 10, 2026 22d ago | Insider Cluster | $503.86 $497.27 | ▼ −1.31% | ▼ −0.81% | $571.38 (+13.40%) |
Sep 9, 2026 23d ago | Insider Cluster | $506.82 $498.48 | ▼ −1.65% | ▼ −0.99% | $571.38 (+12.74%) |
Sep 4, 2026 28d ago | Insider Cluster | $487.61 $502.70 | ▲ +3.09% | ▲ +4.30% | $571.38 (+17.18%) |
Sep 3, 2026 29d ago | Insider Cluster | $488.16 $497.11 | ▲ +1.83% | ▲ +2.98% | $571.38 (+17.05%) |
Aug 28, 2026 5w ago | Insider Cluster | $515.46 $487.61 | ▼ −5.40% | ▼ −5.51% | $571.38 (+10.85%) |
Aug 27, 2026 5w ago | Insider Cluster | $527.91 $492.02 | ▼ −6.80% | ▼ −6.03% | $571.38 (+8.23%) |
Aug 26, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
Aug 25, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access